Koyfin Home > Directory > Health Care > Rigel Pharmaceuticals > Capital Expenditures

Rigel Pharmaceuticals Capital Expenditures Chart (RIGL)

Rigel Pharmaceuticals annual/quarterly Capital Expenditures from 2010 to 2020.
  • Rigel Pharmaceuticals Capital Expenditures for the quarter ending June 06, 2020 was $0m a 900.00% increase of 0m year over year
  • Rigel Pharmaceuticals Capital Expenditures for the last 12 months ending June 06, 2020 was $-2m a 40.17% decrease of -1m year over year
  • Rigel Pharmaceuticals Annual Capital Expenditures for 2019 was $-1m a 23.99% decrease of 0m from 2018
  • Rigel Pharmaceuticals Annual Capital Expenditures for 2018 was $-1m a 85.17% decrease of -1m from 2017
  • Rigel Pharmaceuticals Annual Capital Expenditures for 2017 was $0m a -390.24% increase of 1m from 2016
Other Cash Flow Metrics:
  • Rigel Pharmaceuticals Cash Flow from Operations for the quarter ending December 12, 2018 was $12m a 300.91% increase of 35m year over year
  • Rigel Pharmaceuticals Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $1m a 1,495.75% increase of 15m year over year
  • Rigel Pharmaceuticals Total Revenue for the quarter ending September 09, 2018 was $5m a 26.33% increase of 1m year over year
View Chart On Koyfin

Quarterly RIGL Capital Expenditures Data

06/2020$0m
03/2020$-1m
12/2019$-1m
09/2019$0m
06/2019$0m
03/2019$0m
12/2018$0m
09/2018$0m
06/2018$-1m
03/2018$0m

Annual RIGL Capital Expenditures Data

2019$-1m
2018$-1m
2017$0m
2016$-1m
2015$-1m
2014$0m
2013$-1m
2012$-3m
2011$-2m
2010$-4m